ImmunityBio Inc. Launches Phase 2 Clinical Study of ANKTIVA® to Address Long COVID Symptoms

Reuters

Aug 19, 2025

ImmunityBio Inc. Launches Phase 2 Clinical Study of ANKTIVA® to Address Long COVID Symptoms

ImmunityBio, Inc. has announced the initiation of a new Phase 2 clinical study to evaluate the BioShield™ platform, featuring ANKTIVA® (nogapendekin alfa inbakicept-pmln), in patients suffering from long COVID. This exploratory, single-arm study aims to assess the safety of ANKTIVA when administered subcutaneously and its impact on absolute lymphocyte count. Additionally, the study will explore ANKTIVA's potential to enhance post-COVID NK and CD8+ T cell counts and their immunological functions. With no established treatments currently available for long COVID, this study could offer new insights into potential therapeutic approaches. Results from this study have not yet been presented, as participant recruitment is still underway. The study is supported by ImmunityBio and is complemented by a separate Phase 2 study at the University of California - San Francisco.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819968042) on August 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2560199224"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560199224\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560199224?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560199224","market":"fut","top_or_hot":-1,"title":"ImmunityBio Inc. Launches Phase 2 Clinical Study of ANKTIVA® to Address Long COVID Symptoms","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Inc. Launches Phase 2 Clinical Study of ANKTIVA® to Address Long COVID Symptoms\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> has announced the initiation of a new Phase 2 clinical study to evaluate the BioShield™ platform, featuring ANKTIVA® (nogapendekin alfa inbakicept-pmln), in patients suffering from long COVID. This exploratory, single-arm study aims to assess the safety of ANKTIVA when administered subcutaneously and its impact on absolute lymphocyte count. Additionally, the study will explore ANKTIVA's potential to enhance post-COVID NK and CD8+ T cell counts and their immunological functions. With no established treatments currently available for long COVID, this study could offer new insights into potential therapeutic approaches. Results from this study have not yet been presented, as participant recruitment is still underway. The study is supported by ImmunityBio and is complemented by a separate Phase 2 study at the University of California - San Francisco.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819968042) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Inc. Launches Phase 2 Clinical Study of ANKTIVA® to Address Long COVID Symptoms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Inc. Launches Phase 2 Clinical Study of ANKTIVA® to Address Long COVID Symptoms\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-19 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Inc. Launches Phase 2 Clinical Study of ANKTIVA® to Address Long COVID Symptoms\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> has announced the initiation of a new Phase 2 clinical study to evaluate the BioShield™ platform, featuring ANKTIVA® (nogapendekin alfa inbakicept-pmln), in patients suffering from long COVID. This exploratory, single-arm study aims to assess the safety of ANKTIVA when administered subcutaneously and its impact on absolute lymphocyte count. Additionally, the study will explore ANKTIVA's potential to enhance post-COVID NK and CD8+ T cell counts and their immunological functions. With no established treatments currently available for long COVID, this study could offer new insights into potential therapeutic approaches. Results from this study have not yet been presented, as participant recruitment is still underway. The study is supported by ImmunityBio and is complemented by a separate Phase 2 study at the University of California - San Francisco.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819968042) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL3mwp25:1","article_id":"2560199224","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560199224","pubTimestamp":1755606682,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunityBio, Inc. has announced the initiation of a new Phase 2 clinical study to evaluate the BioShield platform, featuring ANKTIVA , in patients suffering from long COVID. This exploratory, single-arm study aims to assess the safety of ANKTIVA when administered subcutaneously and its impact on absolute lymphocyte count. Additionally, the study will explore ANKTIVA's potential to enhance post-COVID NK and CD8+ T cell counts and their immunological functions. With no established treatments currently available for long COVID, this study could offer new insights into potential therapeutic approaches. Results from this study have not yet been presented, as participant recruitment is still underway. The study is supported by ImmunityBio and is complemented by a separate Phase 2 study at the University of California - San Francisco.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely infor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"ImmunityBio Inc.启动ANKTIVA的2期临床研究®解决新冠后遗症病症状","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"ImmunityBio Inc. Launches Phase 2 Clinical Study of ANKTIVA® to Address Long COVID Symptoms\n    \n\nImmunityBio, Inc. has announced the initiation of a new Phase 2 clinical study to evaluate the BioShield™ platform, featuring ANKTIVA® (nogapendekin alfa inbakicept-pmln), in patients suffering from long COVID. This exploratory, single-arm study aims to assess the safety of ANKTIVA when administered subcutaneously and its impact on absolute lymphocyte count. Additionally, the study will explore ANKTIVA's potential to enhance post-COVID NK and CD8+ T cell counts and their immunological functions. With no established treatments currently available for long COVID, this study could offer new insights into potential therapeutic approaches. Results from this study have not yet been presented, as participant recruitment is still underway. The study is supported by ImmunityBio and is complemented by a separate Phase 2 study at the University of California - San Francisco.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819968042) on August 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}